Afamelanotide (CUV1647)
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polymorphic Light Eruption (PLE)
Conditions
Polymorphic Light Eruption (PLE)
Trial Timeline
May 1, 2007 → Sep 1, 2010
NCT ID
NCT00472901About Afamelanotide (CUV1647)
Afamelanotide (CUV1647) is a pre-clinical stage product being developed by Clinuvel Pharmaceuticals for Polymorphic Light Eruption (PLE). The current trial status is completed. This product is registered under clinical trial identifier NCT00472901. Target conditions include Polymorphic Light Eruption (PLE).
What happened to similar drugs?
0 of 1 similar drugs in Polymorphic Light Eruption (PLE) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
3
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00472901 | Pre-clinical | Completed |
Competing Products
2 competing products in Polymorphic Light Eruption (PLE)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SGT-501 | Solid Biosciences | Phase 1 | 30 |
| Afamelanotide + Placebo | Clinuvel Pharmaceuticals | Phase 3 | 34 |